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Abstract
Introduction: The proper expression of particular glucotransporter (GLUT) isoforms determines a sufficient supply of glucose to tis-
sues. The impairment of cellular glucose transport observed in insulin resistance leads to glucose metabolism disturbances. The aim of this 
study was the estimation of insulin resistance indicators and the quantitative expression of GLUT-1, GLUT-3 and GLUT-4 on peripheral 
blood lymphocytes in prediabetic subjects and persons with a positive family history of type 2 diabetes during 24 months of observation.
Material and methods: The study included 25 prediabetic subjects (according to WHO criteria) and 24 normoglycaemic individuals 
with a positive family history of type 2 diabetes. Twenty three healthy subjects with no family history of type 2 diabetes, matched with 
BMI, served as a control group. All participants were recommended to perform physical activity for at least 140 minutes per week and to 
maintain a low calorie diet. The peripheral blood lymphocytes demonstrating expression of GLUT-1, GLUT-3 and GLUT-4 were labelled 
with the use of indirect immunofluorescence. The expression of GLUT isoforms was investigated by flow cytometry. Cells were stained 
by using anti-human GLUT antibodies and FITC-conjugated immunoglobulin. Flow cytometry was performed using a FACS Calibur 
(Becton-Dickinson). Additionally, we determined: fasting plasma glucose (FPG), insulin and C peptide concentrations, HOMA-IR, BMI 
and WHR. All the tests were performed at baseline, and after 12 and 24 months.
Results: At baseline, prediabetics and subjects with a positive family history of type 2 diabetes were characterised by a much higher 
expression of GLUT-4 compared to control subjects. Twenty four months of lifestyle modification resulted in significant lowering of the 
expression of GLUT-4 on the surface of PBL in both studied groups, with no differences in the expression of GLUT-1 or GLUT-3. Both 
prediabetic subjects and individuals with a positive family history of type 2 diabetes revealed no significant differences in determined 
insulin resistance markers after 24 months of the observation compared to the baseline values.
Conclusions: The estimation of typical GLUT isoforms present on the peripheral blood lymphocytes, as well as the evaluation of insulin 
resistance indicators, are obviously insufficient for monitoring the metabolic disorders progression in the risk groups of type 2 diabetes. The 
decrease in GLUT-4 lymphocyte expression may reflect a positive influence of lifestyle modification on a tissue redistribution of this crucial 
insulin-dependent glucotransporter. The determination of GLUT-4 on the surface of peripheral blood lymphocytes can be a useful tool 
for the evaluation of the efficacy of therapeutic actions in subjects at high risk of type 2 diabetes. (Pol J Endocrinol 2012; 63 (3): 212–219)
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Streszczenie
Wstęp: Właściwa ekspresja poszczególnych izoform glukotransporterów (GLUT) warunkuje odpowiednie zaopatrzenie tkanek w glukozę. 
Upośledzenie dokomórkowego transportu glukozy obserwowane w warunkach insulinooporności prowadzi do zaburzeń metabolizmu 
glukozy. Celem badania była ocena wskaźników insulinooporności oraz ilościowej ekspresji GLUT-1, GLUT-3 i GLUT-4 na limfocytach 
krwi obwodowej osób ze stanem przedcukrzycowym oraz osób z dodatnim wywiadem rodzinnym w kierunku cukrzycy typu 2 w trakcie 
24-miesięcznej obserwacji.
Materiał i metody: Do badania włączono 25 osób ze stanem przedcukrzycowym (wg kryteriów WHO) i 24 osoby z normoglikemią 
z dodatnim wywiadem rodzinnym w kierunku cukrzycy typu 2. Grupę kontrolną stanowiły 23 zdrowe osoby bez wywiadu rodzinnego 
w kierunku cukrzycy, dobrane pod względem BMI. Wszystkim uczestnikom badania zalecono zwiększenie aktywności fizycznej do co 
najmniej 140 min tygodniowo oraz stosowanie diety niskokalorycznej. Do znakowania limfocytów krwi obwodowej wykazujących ekspresję 
GLUT-1, GLUT-3 i GLUT-4 użyto techniki immunofluorescencji pośredniej z wykorzystaniem swoistych przeciwciał anty-ludzkich GLUT 
oraz immunoglobulin sprzężonych z FITC. Ekspresję poszczególnych izoform GLUT oznaczano za pomocą cytometrii przepływowej 
przy użyciu cytometru FACS Calibur (Becton-Dickinson) Dodatkowo oznaczano glikemię na czczo, stężenie insuliny i C-peptydu na 
czczo, wskaźniki HOMA-IR, BMI oraz WHR. Wszystkie oznaczenia były wykonywane wyjściowo, po 12 i po 24 miesiącach obserwacji.
Wyniki: W chwili rozpoczęcia badania osoby ze stanem przedcukrzycowym oraz osoby z dodatnim wywiadem rodzinnym w kierunku 
cukrzycy typu 2 charakteryzowały się znacznie wyższą ekspresją GLUT-4 w porównaniu z grupą kontrolną. W czasie 24 miesięcy od 
wdrożenia modyfikacji stylu życia zaobserwowano istotny spadek ekspresji GLUT-4 na limfocytach krwi obwodowej w obu badanych 
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grupach ryzyka, przy braku różnic w ekspresji GLUT-1 i GLUT-3. Zarówno w grupie osób ze stanem przedcukrzycowym, jak i wśród 
osób z dodatnim wywiadem rodzinnym w kierunku cukrzycy typu 2 po 24 miesiącach nie stwierdzono istotnych statystycznie różnic 
w zakresie badanych wskaźników insulinopoorności w porównaniu z wartościami wyjściowymi.
Wnioski: Ani oznaczanie typowych dla limfocytów krwi obwodowej izoform GLUT, ani ocena wskaźników insulinooporności są 
niewystarczające do monitorowania progresji zaburzeń metabolicznych w grupach ryzyka cukrzycy typu 2. Spadek ekspresji GLUT-4 
na limfocytach jest prawdopodobnie odzwierciedleniem pozytywnego wpływu modyfikacji stylu życia na tkankową redystrybucję tego 
kluczowego insulinozależnego transportera glukozy. Oznaczanie GLUT-4 na limfocytach krwi obwodowej może być wartościowym 
narzędziem do oceny skuteczności interwencji terapeutycznych w grupach ryzyka cukrzycy typu 2. (Endokrynol Pol 2012; 63 (3): 212–219)
Słowa kluczowe: stan przedcukrzycowy, dodatni wywiad rodzinny, cukrzyca typu 2, insulinooporność, transport glukozy, glukotransportery 
(GLUT), limfocyty
Introduction
Given the growing epidemic of obesity, diabetes preven-
tion is becoming one of the most important and most 
difficult problems not only in diabetology, but the whole 
of modern medicine. According to WHO data, there 
are currently more than 220 million people worldwide 
who suffer from diabetes and it is anticipated that this 
number will have doubled by 2030 [1]. Sedentary life-
styles and high-calorie diets which lead to overweight 
and obesity are regarded as the fundamental causes of 
the increase in the incidence of pre-diabetic and diabetic 
state, not only among adults but also in children and 
adolescents [2]. It is estimated that in Poland about 
2 million people have diabetes and approximately 
4 million people are in pre-diabetic state [3]. Accord-
ing to recent studies, in USA in 2007 the pre-diabetes 
problem affected about 57 million American adults [4]. 
Proper identification of persons at high risk of type 2 
diabetes is required to take appropriate strategic actions 
aimed at preventing the development of diabetes, or at 
least delaying this disease and its related complications.
Among all risk groups of type 2 diabetes, two seem 
to be exceptionally significant: pre-diabetic subjects and 
first-degree relatives of type 2 diabetic patients.
The concept of pre-diabetes means impaired fast-
ing glucose (IFG), i.e. fasting plasma glucose values 
of 5.6–6.9 mmol/L, and/or impaired glucose tolerance 
(IGT), a condition in which blood glucose in the sec-
ond hour of OGTT is in the range of 7.8–11.0 mmol/L). 
A relatively new criterion for pre-diabetes diagnosis, 
recognised by the American Diabetes Association 
(ADA), is the percentage of glycated haemoglobin 
HbA1c corresponding to 5.7–6.4% [5]. Pre-diabetic 
state, which is an intermediate stage between nor-
moglycaemia and diabetes, can manifest many years 
before the diagnosis of diabetes. It is believed that 
within 3–5 years as many as 25% of people with 
diagnosed impaired fasting glucose and/or impaired 
glucose tolerance can develop diabetes [6].
The constant increase in the prevalence of type 2 dia-
betes results in a growing number of subjects burdened 
with a family history of this disease [7]. For many years, 
this disease has been considered as a family occurring 
disease, which means an increased risk of the develop-
ment of type 2 diabetes in relatives of type 2 diabetic 
subjects [8, 9]. It is commonly known that the risk of the 
development of type 2 diabetes depends on both the 
degree of relation (i.e. the higher the degree, the greater 
the risk) and the number of family members suffering 
from diabetes. It has been revealed that in families with 
a single case of type 2 diabetes, the relatives are character-
ized by 40% diabetes susceptibility during their lifetime. 
Furthermore, type 2 diabetes coexists more often in 
monozygotic twins than heterozygotic ones. The prob-
ability of type 2 diabetes development in monozygotic 
twins reaches as much as 95% [10]. Moreover, it has been 
proven that in the offspring of couples in which both 
parents are affected with type 2 diabetes, the insulin 
resistance syndrome precedes the onset of the disease 
for ten years [11].
Given the alarming incidence of pre-diabetes, 
taking effective primary prevention in this group of 
people would benefit a large number of individual 
patients, as well as reap huge social and economic 
benefits. As recommended by ADA and the Polish 
Diabetes Association (PTD) for the year 2011, if there 
are no symptoms of hyperglycaemia, the test for dia-
betes should be performed every three years for each 
person over 45, and regardless of age once a year in 
people with other risk factors [12].
These principles for screening diabetes are based 
on the assessment of glycaemic control, which means 
that diagnosis of the disease comes at a relatively late 
stage, since it is known that not only diabetes, but ‘hy-
perglycaemia not related to diabetes’ is associated with 
a significantly increased risk of cardiovascular disease, 
which has been proven in large clinical trials [13, 14]. This 
risk is even greater when there is coexistence of impaired 
fasting glucose and impaired glucose tolerance [15–17].
For many years, clinicians have sought measur-
able exponents of changes in the pre-hyperglycaemic 
phase hoping to develop more sensitive diagnostic 
tests in the future. In 2004, an increase in the amount 
of proteins transporting glucose by facilitated dif-
fusion (glucose transporters) on peripheral blood 
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lymphocytes in patients with type 2 diabetes was 
observed [18]. The authors of a further work suggested 
that changes in the expression of glucose transporter 
may precede the laboratory exponent abnormalities 
in diabetes [19].
Therefore, with the above objective, it seems use-
ful to assess the possible relationship between the 
expression of GLUT transporter family and biochemi-
cal markers of glucose metabolism disorders, as well 
as insulin resistance indicators, in patients at risk of 
diabetes.
Aim of study
The aim of this study was to compare biochemical mark-
ers of insulin resistance and quantitative protein expres-
sion of GLUT-1, GLUT-3 and GLUT-4 on the surface of 
peripheral blood lymphocytes in the risk groups of type 
2 diabetes: pre-diabetic subjects and individuals with 
a positive family history of type 2 diabetes, at baseline 
and after 24 months of observation.
Material and methods
The study included 25 people with impaired fasting 
glucose and/or impaired glucose tolerance, diagnosed 
on the basis of an OGTT test according to WHO crite-
ria and 24 normoglycaemic individuals with a positive 
fami ly history of type 2 diabetes. The type of family 
relation in the group of subjects with a positive family 
history of type 2 diabetes is presented in Table I. The 
control group consisted of 23 normoglycaemic people 
with a negative family history of diabetes, matched 
for BMI. The study included people of both sexes aged 
35–75 years. All participants received information on 
the aim and course of the experiment, and were included 
in the study after giving informed written consent.
The study excluded individuals:
— with renal insufficiency (serum creatinine > 2.5 mg/dL);
—  with liver disease (transaminase activity ³ 3 times 
upper limit of normal);
—  with symptomatic heart failure;
—  with cancer in the last five years;
—  using diabetogenic drugs (e.g. systemic cortico-
steroids, oral contraceptives, thiazide diuretics, 
miconazole);
—  abusing drugs or alcohol, and those addicted to 
drugs in the past year;— pregnant women, lactat-
ing women.
Patients were enrolled in the study on the basis 
of an internal examination, with particular emphasis 
on interviews (standardized survey to gather demo-
graphic, environmental and clinical data) and labora-
tory tests. The characteristics of participants are shown 
in Table II.
All participants were recommended to perform 
physical activity for at least 140 minutes per week and 
to maintain a low-calorie diet with a minimal energy 
reduction of 500 kcal per day. These recommendations 
were notified every six months during the observation 
period. The verification of introduced lifestyle modifica-
tion was based on a standardized questionnaire consist-
ing of questions referring to the kind, frequency and 
length of performed physical activity. In all subjects at 
baseline and after 24 months, fasting plasma glucose 
determination (enzymatic method), serum fasting 
insulin and fasting C-peptide (radioimmunoassay) 
were assessed and the HOMA-IR indicator was cal-
culated [20]. During the first and the last visit, the oral 
glucose tolerance test according to WHO procedures 
was also carried out.
Lymphocytes were isolated to determine the 
quantitative expression of glucose transporters 
(GLUT) on their surface from fasting blood samples 
(10 mL), taken from all participants. Lymphocyte iso-
lation was performed using Gradisol L (Aqua-Med-
ica, Poland) (2,800 rpm, 20 min.). The harvested 
cells were washed twice in 0.9% NaCl solution 
(1,800 rpm, 10 min.). After this procedure, the cells 
were suspended in a volume called ‘Transport solu-
Table I. Type of family relation in the group of subjects with 
a positive family history of type 2 diabetes mellitus
Tabela I. Rodzaj pokrewieństwa w grupie osób z dodatnim 
wywiadem rodzinnym w kierunku cukrzycy typu 2
First degree relative with 
type 2 diabetes mellitus
Number  
of cases
Percentage  
of cases (%)
Father 7/24 29.16
Mother 11/24 45.83
Brother/sister 3/24 12.50
Father + brother/sister 1/24 4.16
Mother + brother/sister 1/24 4.16
Father + mother 1/24 4.16
Table II. Characteristics of the studied groups at baseline
Tabela II. Charakterystyka badanych grup w chwili rozpoczęcia 
badania
Parameter Control  
group
Positive  
family history
Prediabetes
Number of 
participants
23 24 25
Sex (M/F) 10/13 11/13 9/16
Age (years) 45.0 ± 8.0 46.6 ± 9.7 50.6 ± 8.0
BMI [kg/m2] 30.7 ± 3.0 29.5 ± 4.6 30.1 ± 5.1
WHR 0.88 ± 0.09 0.87 ± 0.11 0.87 ± 0.06
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tions’ [21] so that the density in each sample was 106 
cells/mL. To label the cells that express the surveyed 
GLUT proteins, the single-colour indirect immu-
nofluorescence technique was used. For this pur-
pose, monoclonal antibodies (MoAb) anti-GLUT-1, 
anti-GLUT-3, anti-GLUT-4, and non-specific anti-
body marking F(ab‘) 2 immunoglobulin fragment 
conjugated with fluorescein isothiocyanate (FITC) 
were used. A negative control to exclude cell au-
tofluorescence, and a positive control to exclude 
nonspecific binding of FITC-labelled antibodies, 
were also carried out. The quantitative estimation of 
the glucose transporters was executed by using flow 
cytometry. For data acquisition and analysis, a FACS 
Calibur flow cyto meter with CellQuest programme 
(Becton-Dickinson) was used.
Statistical methods
The obtained data was presented as mean values and 
standard deviations. Quantitative parameters were 
compared using the Aspin-Welch test. The significance 
level threshold was p = 0.01.
Results
Individuals with a positive family history  
of type 2 diabetes
At the beginning of the study, individuals with a positive 
family history of type 2 diabetes compared to the control 
group were characterised by insignificant differences 
in fasting glucose (5.19 ± 0.3 v. 5.27 ± 0.04 mmol/L, 
p = ns) (Fig. 1), glucose at 120 min. of OGTT (5.8 ± 1.06 
v. 5.66 ± 1.0 mmol/L, p = ns) (Fig. 2), and also in serum 
C-peptide levels (2.35 ± 0.84 v. 1.96 ± 0.56 ng/mL, 
p = ns) (Fig. 3), but significantly higher levels of fasting 
insulin (10.13 ± 4.74 v. 3.49 ± 2.51 mU/L, p < 0.01), and 
HOMA-IR (2.34 ± 1.14 v. 0.82 ± 0.62) (Figs. 4, 5).
The two-year study of the subjects burdened with 
a positive family history of type 2 diabetes showed 
no significant changes in fasting glucose (5.19 ± 0.3 
v. 5.38 ± 0.58 mmol/L) or glucose at 120 min. of OGTT 
(5.8 ± 1.06 v. 5.99 ± 1.38 mmol/L) (Figs. 1, 2), as well 
as fasting insulin (10.13 ± 4.74 v. 9.61 ± 4.08 mU/L), 
serum C-peptide (2.35 ± 0.84 v. 2.57 ± 0.63 ng/mL), or 
HOMA-IR (2.34 ± 1.14 v. 2.34 ± 1.14) compared to base-
line values (Figs. 3–5). There were also no statistically 
significant differences in BMI (29.5 ± 4.55 v. 30.8 ± 5.61 
kg/m²) or WHR (0.87 ± 0.06 v. 0.9 ± 0.07) (Figs. 6, 7).
During the two-year follow-up, there were no signif-
icant differences in expression of GLUT-1 (29.7 ± 10.36 
v. 30.62 ± 11.72%) or GLUT-3 protein (7.54 ± 3.3 
v. 8.24 ± 8.24%) (Figs. 8, 9). However, a significant 
decrease was observed with the expression of GLUT-4 
protein (18.93 ± 12.71 v. 9.35 ± 6.07%, p < 0.01) (Fig. 10).
Prediabetic subjects
At the start of the study, a group of people with pre- 
-diabetic state in comparison with the control group was 
characterised not only by significantly higher fasting 
glucose (6.14 ± 0.53 v. 5.27 ± 0.04 mmol/L, p < 0.01) 
(Fig. 1) and glucose at 120 min. of OGTT (8.16 ± 1.61 
Figure 1. Comparison of fasting plasma glucose in the studied 
groups at baseline and after 24 months with the control group
Rycina 1. Porównanie glikemii na czczo w badanych grupach 
wyjściowo i po 24 miesiącach w odniesieniu do grupy kontrolnej
Figure 2. Comparison of glucose in 120 minutes of OGTT in the 
studied groups at baseline and after 24 months with the control group
Rycina 2. Porównanie glikemii w 120. minucie OGTT w badanych 
grupach wyjściowo i po 24 miesiącach w odniesieniu do grupy kontrolnej
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Similarly to the previously mentioned group, 
a two-year observation of the pre-diabetic state showed 
no significant increase in fasting glucose (6.14 ± 0.53 
v. 6.49 ± 0.88 mmol/L) or glucose at 120 min. of OGTT 
(8.16 ± 1.61 v. 8.34 ± 2.62 mmol/L) (Figs. 1, 2), as well as 
Figure 4. Comparison of fasting insulin in the studied groups at 
baseline and after 24 months with the control group
Rycina 4. Porównanie stężenia insuliny na czczo w badanych 
grupach wyjściowo i po 24 miesiącach w odniesieniu do grupy 
kontrolnej
Figure 3. Comparison of fasting C-peptide in the studied groups 
at baseline and after 24 months with the control group
Rycina 3. Porównanie stężenia C-peptydu na czczo w badanych 
grupach wyjściowo i po 24 miesiącach w odniesieniu do grupy kontrolnej
v. 5.66 ± 1.0 mmol/L, p < 0.01) (Fig. 2), but also signifi-
cantly higher rates of insulin resistance: fasting insulin 
(13.05 ± 7.51 v. 3.49 ± 2.51 mU/L, p < 0.01), serum 
C-peptide (2.81 ± 1.09 v. 1.96 ± 0.56 ng/mL, p < 0.01), 
and HOMA-IR (3.52 ± 1.94 v. 0.82 ± 0.62) (Figs. 3–5).
Figure 5. Comparison of HOMA-IR in the studied groups at 
baseline and after 24 months with the control group 
Rycina 5. Porównanie wskaźnika HOMA-IR w badanych grupach 
wyjściowo i po 24 miesiącach w odniesieniu do grupy kontrolnej
Figure 6. Comparison of BMI in the studied groups at baseline 
and after 24 months with the control group
Rycina 6. Porównanie BMI w badanych grupach wyjściowo i po 
24 miesiącach w odniesieniu do grupy kontrolnej
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fasting insulin (13.05 ± 7.51 v. 13.02 ± 8.86 mU/L), serum 
C-peptide (2.81 ± 1.09 v. 3.28 ± 1.7 ng/mL), HOMA-IR 
(3.52 ± 1.94 v. 3.93 ± 3.37) (Figs. 3–5), BMI (30.14 ± 5.11 
v. 30.8 ± 5.61 kg/m²) or WHR (0.87 ± 0.06 v. 0.9 ± 0.07) 
(Figs. 6 and 7) compared to baseline values.
During the two-year follow-up, no significant 
differences in expression of GLUT-1 (33.42 ± 13.38 
v. 31.53 ± 14.10%) or GLUT-3 protein (8.22 ± 3.84 
v. 7.48 ± 3.75%) were shown (Figs. 8 and 9). The study 
revealed a significant decrease in the expression of 
Figure 7. Comparison of WHR in the studied groups at baseline 
and after 24 months with the control group
Rycina 7. Porównanie WHR w badanych grupach wyjściowo i po 
24 miesiącach w odniesieniu do grupy kontrolnej
Figure 8. Comparison of the quantitative expression of GLUT-1 on 
the surface of peripheral blood lymphocytes in the studied groups 
at baseline and after 24 months with the control group
Rycina 8. Porównanie ilościowej ekspresji GLUT-1 na limfocytach 
krwi obwodowej w badanych grupach wyjściowo i po 24 miesiącach 
w odniesieniu do grupy kontrolnej
Figure 10. Comparison of the quantitative expression of GLUT-4 
on the surface of peripheral blood lymphocytes in the studied groups 
at baseline and after 24 months with the control group
Rycina 10. Porównanie ilościowej ekspresji GLUT-4 na 
limfocytach krwi obwodowej wyjściowo i po 24 miesiącach w 
odniesieniu do grupy kontrolnej
Figure 9. Comparison of the quantitative expression of GLUT-3 on 
the surface of peripheral blood lymphocytes in the studied groups 
at baseline and after 24 months with the control group
Rycina 9. Porównanie ilościowej ekspresji GLUT-3 na limfocytach 
krwi obwodowej w badanych grupach wyjściowo i po 24 miesiącach 
w odniesieniu do grupy kontrolnej
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GLUT-4 protein (20.21 ± 14.44 v. 9.65 ± 5.73%, p < 0.01) 
on the surface of prediabetic subjects’ lymphocytes. The 
same phenomenon was observed in the positive family 
history group (Fig. 10).
In the control group, the expression of particular 
glucose transporter isoforms on the surface of pe-
ripheral blood lymphocytes was as follows: GLUT-1 
23.62 ± 13.87%, GLUT-3 7.44 ± 4.33%, and GLUT-4 
3.43 ± 2.77%.
Discussion
The vast majority of research on the intracellular trans-
port of glucose in carbohydrate metabolism disorders 
has focused on patients with diabetes, and in the avail-
able literature most articles focus on risk groups of 
type 2 diabetes, including people with pre-diabetic state 
and individuals burdened with a positive family history 
of type 2 diabetes [22, 23].
Many years ago, it was shown that people with 
type 2 diabetes are characterised by a higher ex-
pression of glucose transporters on the surface of 
peripheral blood lymphocytes compared to people 
with normoglycaemia [18, 19]. It was found that not 
only in the case of chronic hyperglycaemia, but also 
in conditions of prolonged hypoglycaemia, there is 
an increased expression of glucose transporters on 
the surface of leukocytes. It has been shown that 
hypoglycaemia induces a significant increase in the 
expression of GLUT-3 proteins on the surface of 
monocytes, as well as in GLUT-4 and GLUT-3 proteins 
on the surface of granulocytes [24]. In this experiment, 
there was no detection of glucose transporters on the 
surface of lymphocytes, which contradicts the results 
of subsequent studies [18, 19, 25].
We demonstrated in this study a decrease in the 
expression of the main insulin-dependent glucose 
transporter, GLUT-4, during the 24-month follow-up. 
This could attest to the positive impact of lifestyle 
modification on the tissue redistribution of the protein. 
It is assumed that increased physical activity leads to 
increased expression of GLUT-4 on the surface of cells 
that are most sensitive to the action of insulin (muscle 
cells, adipocytes), while in the remaining cells, the 
reverse process is observed. Increased expression of 
GLUT-4 mRNA and/or protein in the cells of skeletal 
muscle following exercise has been confirmed in several 
studies [26–30]. Similar results were obtained in the case 
of experiments on adipocyte models [31]. The authors 
of the latter work have also shown that an increase in 
the expression of GLUT-4 on the surface of adipocytes 
is accompanied by improved insulin sensitivity and 
decreased plasma concentrations of retinol binding 
protein (RBP4).
At the beginning of our study, the observation of 
the GLUT-4 protein expression of lymphocytes in the 
group of prediabetic people was almost 6-fold higher 
than in healthy subjects, which corresponds with the 
results of the experiments mentioned above [18, 19, 25]. 
However, there are reports that diabetes is characterised 
not by increased, but by reduced, expression of glucose 
transporters on leukocyte cell surface [32]. The cited 
study, comparing the expression of GLUT proteins in 
specific leukocyte subpopulations in patients with type 2 
diabetes and healthy subjects, showed lower expression 
of GLUT-3 in granulocytes, monocytes and lymphocytes 
in patients with diabetes, while a lower expression of 
GLUT-4 was demonstrated only for monocytes.
Our study revealed that disturbances of the cellular 
glucose transport exist in subjects who are normogly-
caemic but burdened with a family history of type 2 
diabetes, which means that these abnormalities precede 
possible glucose metabolism disorders. Our findings are 
in line with the study concerning glucose transport in 
skeletal muscle obtained from first-degree relatives of 
type 2 diabetic patients, which found a 38% decrease of 
insulin-stimulated glucose transport in these subjects 
[33]. The authors of the cited study suggest that the 
impairment of glucose transport should be recognised 
as an early event in the pathogenesis of type 2 diabetes.
The observed alterations in the expression of GLUT-4 
were not accompanied by body weight reduction or 
a decrease of insulin resistance indicators. Similar results 
were found in The Oslo Diet and Exercise Study (ODES), 
in which the authors did not find any correlation 
between lifestyle modification and insulin resistance 
indicators [34]. The decrease of GLUT-4 protein levels 
during 24 months of observation may reflect the positive 
influence of lifestyle modification. However, it cannot 
be unambiguously stated, because of the following limi-
tations of our study: the lack of strict supervision over 
putting into practice the recommendations concerning 
the physical activity and low-calorie diet, the relatively 
short time of the observation, and the limited number 
of participants.
Therefore, it cannot be unequivocally stated that 
the decrease in GLUT-4 expression in patients in the 
pre-diabetic state observed over the 24 month period 
is not the result of lifestyle modification, but constitutes 
a part of the natural history of the disease, which would 
acknowledge the fact that changes in the expression of 
GLUT-4 were not accompanied by weight reduction or 
a decrease in the indicators of insulin resistance.
The current state of medical knowledge does not 
permit overcoming these concerns, because intracellular 
glucose transport issues remain largely unclear. Further 
discoveries in this area are likely to contribute to a better 
understanding of the pathophysiology of diabetes, and 
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may allow the development of more sensitive diagnostic 
tests, enabling early identification of those at the highest 
risk of diabetes. Such people would gain greater benefits 
from preventive actions.
Conclusions
The two-year observation did not reveal any significant 
differences either in studied insulin resistance indica-
tors or GLUT-1 and GLUT-3 expression on lymphocytes 
in the prediabetic subjects as well as in subjects with 
a positive family history of type 2 diabetes.
The assessment of the expression of glucose trans-
porters isoforms typical on peripheral blood cells, such 
as GLUT-1 and GLUT-3, and also an examination of 
insulin resistance indicators, are insufficient to monitor 
the progression of metabolic disorders in individuals at 
high risk of type 2 diabetes.
The determination of GLUT-4 on the surface of 
peripheral blood lymphocytes can be a useful tool to 
evaluate the efficacy of therapeutic actions in predia-
betic subjects as well as in subjects with a positive family 
history of type 2 diabetes.
The decrease in expression of the main insulin-de-
pendent glucose transporter, GLUT-4, on the surface of 
lymphocytes in the examined subjects is probably a re-
flection of the positive impact of lifestyle modification 
on the tissue redistribution of that glucose transporter.
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